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Abstract
Background: Mutations in the PRNP gene account for ~15% of all prion disease cases. Little is
understood about the mechanism of how some of these mutations in PRNP cause the protein to
aggregate into amyloid fibers or cause disease. We have taken advantage of a chimeric protein
system to study the oligopeptide repeat domain (ORD) expansions of the prion protein, PrP, and
their effect on protein aggregation and amyloid fiber formation. We replaced the ORD of the yeast
prion protein Sup35p with that from wild type and expanded ORDs of PrP and compared their
biochemical properties in vitro. We previously determined that these chimeric proteins maintain
the [PSI+] yeast prion phenotype in vivo. Interestingly, we noted that the repeat expanded chimeric
prions seemed to be able to maintain a stronger strain of [PSI+] and convert from [psi-] to [PSI+]
with a much higher frequency. In this study we have attempted to understand the biochemical
properties of these chimeric proteins and to establish a system to study the properties of the ORD
of PrP both in vivo and in vitro.
Results: Investigation of the chimeric proteins in vitro reveals that repeat-expansions increase
aggregation propensity and that the kinetics of fiber formation depends on the number of repeats.
The fiber formation reactions are promiscuous in that the chimeric protein containing 14 repeats
can readily cross-seed fiber formation of proteins that have the wild type number of repeats.
Morphologically, the amyloid fibers formed by repeat-expanded proteins associate with each other
to form large clumps that were not as prevalent in fibers formed by proteins containing the wild
type number of repeats. Despite the increased aggregation propensity and lateral association of the
repeat expanded proteins, there was no corresponding increase in the stability of the fibers formed.
Therefore, we predict that the differences in fibers formed with different repeat lengths may not
be due to gross changes in the amyloid core.
Conclusion:  The biochemical observations presented here explain the properties of these
chimeric proteins previously observed in yeast. More importantly, they suggest a mechanism for
the observed correlation between age of onset and disease severity with respect to the length of
the ORD in humans.
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Background
The aggregation of various proteins is implicated in many
diseases, including neurodegenerative disorders [1]. Many
of the aggregating proteins form amyloid fibers that are
the hallmark of diseases such as Alzheimer's, Parkinson's
and Huntington's disease [2]. Amyloid fibers are also
associated with prion diseases. The prion protein (PrP)
can misfold and aggregate to form amyloid fibers, leading
to neurodegenerative prion diseases [3,4]. The three pri-
mary means of acquiring prion diseases are as follows: 1)
infection – can be transmitted by the ingestion of meat
obtained from diseased animals, 2) spontaneous – occurs
sporadically via unknown mechanism(s) and 3) inherited
– mutations in the PRNP gene encoding PrP [4,5]. About
15% of prion disease cases are associated with mutations
in the PRNP gene and ~85% of the cases are classified as
sporadic [5]. A unique characteristic of prion diseases is
that an aggregated form of the PrP protein can be infec-
tious [6], however infectious forms of prion disease are
rare in comparison to inherited and sporadic cases.
Although the mechanism of pathogenesis of prion dis-
eases is not well understood, this process does not neces-
sarily result from a genetic mutation [3,7,8]. It is
hypothesized that the aggregated form of PrP is infectious
and acts as a template to change the native conformation
of PrP and cause it to also aggregate [8]. Familial forms of
prion diseases include Creutzfeldt-Jakob disease (CJD),
Gerstmann-Sträussler-Scheinker syndrome (GSS), and
Fatal Familial Insomnia (FFI). Several different mutations
in PRNP are associated with prion diseases, but the mech-
anisms by which the various mutations cause disease are
not always clearly understood [5]. In this study, we use a
model system created to investigate some aspects of an
inherited form of prion disease that results from inser-
tional mutations in PRNP to cause diseases such as GSS
and CJD [9].
PrP is a 23 kD protein that can be divided into two major
domains. The C terminus is implicated in the formation
of amyloid fibers in the infectious form of the disease
[10,11]. The N-terminal domain is largely unstructured;
however, some mutations in this domain are linked to
disease and influence PrP fibrillization and amyloid prop-
agation in vitro [12]. The N-terminal region contains an
oligopeptide repeat domain (ORD) that consists of five
repeats of an eight amino acid peptide with the consensus
sequence PHGGGWGQ [13]. Expansion of the ORD by
the addition of two to nine extra repeats causes a domi-
nantly inherited form of prion disease [5,14-18]. The
number of repeats present is inversely correlated, albeit
weakly, with the age of onset of disease [19]. In addition,
recombinant PrP peptides with expansions of the ORD
display increased aggregation in vitro [20]. A transgenic
mouse model of one such ORD expansion, Tg(PG14), in
which the number of repeats in the ORD is increased to
14, develops a fatal neurodegenerative disorder [21,22].
The disease manifests spontaneously and the Tg(PG14)
mice develop neurological illness that features ataxia,
neuropathological abnormalities and the accumulation of
PrP in the brain [21,23]. Furthermore, the ORD has been
shown to bind many divalent cations such as copper,
manganese and zinc [24,25]. It has been proposed that
binding of these metals to the ORD may affect the struc-
tural properties of PrP and thereby affect disease progres-
sion [24]. Thus, many lines of evidence from human,
mouse and biochemical studies illustrate a vital role for
the ORD in some prion diseases.
Prion proteins also exist in yeast [26]. However, unlike the
mammalian prion protein that causes disease when aggre-
gated, yeast prions function as epigenetic factors of phe-
notypic inheritance [27-29]. One well-studied prion in
yeast is the [PSI+] prion, whose protein determinant is
Sup35p [30-32]. Sup35p is the Saccharomyces cerevisiae
eRF3 (eukaryotic release factor 3) involved in modulating
translation termination at stop codons in messenger
RNAs. When Sup35p is in the prion conformation
([PSI+]), the aggregated protein is presumably no longer
functional in translation termination, resulting in non-
sense suppression [32,33].
Sup35p is a 76.5 kD protein that can be divided into three
domains. The C-terminal domain is necessary and suffi-
cient for the function of the protein in translation termi-
nation [30,34,35]. The amino-terminal region of Sup35p
is considered the prion-forming domain (PFD) [30,35].
The minimum region required for maintenance of the
[PSI+] prion is amino acids 1–93 [36,37], but this region
is not sufficient to maintain different prion strains [38].
The N-terminal domain (N) is rich in glutamine and
asparagine (Q/N) residues. The middle domain (M) is
rich in charged amino acids [35]. Interestingly, the N-ter-
minal domain of Sup35p contains an ORD that consists
of five and a half repeats with the consensus sequence
PQGGYQQYN [39] that is similar to the ORD in PrP.
Deletion of even one repeat from the wild type Sup35 pro-
tein prevents efficient formation of the [PSI+] prion [36].
Expansion of the Sup35p repeats increases the frequency
of conversion from the [psi-] to the [PSI+] state [39]. Previ-
ous studies have shown that the [PSI+] prion phenotype
can be maintained in vivo when the Sup35p repeat region
is replaced by the PrP repeat sequence[36,40]. The
Sup35p repeats were replaced with five, eight, 11 or 14
PrP repeats to generate chimeras referred to as SP5 (Sup35
with 5 PrP repeats), SP8, SP11, and SP14, respectively
[40]. All chimeras were capable of propagating a prion
and maintained translation termination function in the
non-prion state. Interestingly, the SP14 chimeric protein
spontaneously converted cells from the non-prion [sp14-]
state to the [SP14+] prion state at a frequency that isBMC Biochemistry 2008, 9:7 http://www.biomedcentral.com/1471-2091/9/7
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approximately four orders of magnitude higher than that
of the spontaneous conversion of wild type Sup35p from
the [psi-] to the [PSI+] state. This increase in the spontane-
ous conversion of the repeat-expanded chimera to the
prion state may be due to an increase in the inherent pro-
pensity of the repeat-expanded proteins to aggregate and
form amyloid fibers. However, the interpretation of the
data is complicated by the requirement for the [RNQ+]
prion for the enhanced induction in vivo.
Here, we take advantage of the chimeric Sup35-PrP prion
protein system to study the effect of the PrP repeat expan-
sions on the in vitro aggregation of the prion protein. The
advantage of using the Sup35-PrP chimera lies in the abil-
ity to readily study properties of protein aggregation both
in vitro and in vivo. By using the chimeric Sup35-PrP pro-
tein system, the effects of mutations associated with prion
disease can be assessed by fiber formation in vitro and
compared to their in vivo behavior in yeast, and vice versa.
In this study, we investigate the properties of the PrP ORD
and disease-associated repeat expansion on amyloid fiber
formation in an effort to distinguish between the proper-
ties of an ORD with non-pathological versus pathological
repeat lengths. To this end, we have purified recombinant
protein that encompasses the NM region of wild type
Sup35p (Sup35NM) and that of chimeras with five
(SP5NM), eight (SP8NM), 11 (SP11NM) or 14 (SP14NM)
repeats of PrP precisely substituted for the Sup35p ORD
and characterized their kinetic, morphological and bio-
chemical properties.
Results
The expanded ORD of PrP decreases the lag phase of fiber 
formation
We purified the NM region of wild type Sup35p
(Sup35NM) and chimeras with five (SP5NM), eight
(SP8NM), 11 (SP11NM), and 14 (SP14NM) repeats. The
purified recombinant proteins were used to assess the
influence of ORD repeat expansions on amyloid fiber for-
mation by monitoring the change in Thioflavin-T (Th-T)
fluorescence over time. Wild type Sup35NM had a lag
phase of ~5,000 seconds followed by a logarithmic
growth phase (Fig. 1A). However, in the presence of seeds
(sonicated preformed fibers 2.5% w/w), the lag phase was
completely eliminated and fiber formation occurred rap-
idly (Fig. 1A) as reported previously [41]. We then assayed
fiber formation of the chimeric proteins SP5NM, SP8NM,
SP11NM and SP14NM. The formation of chimeric
SP5NM fibers in an unseeded reaction showed a lag phase
(~5,000 seconds; Fig. 1B) similar to that observed with
wild type Sup35NM (Fig. 1A). The repeat-expanded chi-
meras SP8NM, SP11NM, and SP14NM had a negligible
lag phase in unseeded reactions (Fig. 1B). Strikingly, the
kinetics of fiber formation of the expanded ORD chimeric
proteins in the unseeded reactions was similar to the
kinetics of fiber formation of Sup35NM in the presence of
pre-formed fiber seeds. In an effort to determine if the lack
Fiber formation of ORE chimeras is faster than that with the wild type ORD of PrP Figure 1
Fiber formation of ORE chimeras is faster than that with the wild type ORD of PrP. Recombinant protein was 
diluted from denaturant (120 ×) to 2.5 μM and fiber formation was followed by Th-T fluorescence. Graphs are plotted as 
%RFU (Relative fluorescence units) versus time. (A) Sup35NM unseeded (solid line) and Sup35NM seeded with sonicated pre-
formed fibers (dotted line). Reaction was seeded with 2.5% (w/w) of preformed sonicated fibers. (B) Unseeded reactions 
Sup35NM (solid line), SP5NM (dotted line), SP8NM (short dashed line), SP11NM (dotted and dashed line) and SP14NM (long 
dashed line).BMC Biochemistry 2008, 9:7 http://www.biomedcentral.com/1471-2091/9/7
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of lag phase associated with SP14NM fiber formation was
simply due to seeds forming in the presence 6M GdHCl,
we resuspended SP14NM protein in 8 M urea instead.
When protein was diluted out from 8 M urea, we observed
the same rate of fiber formation and no lag phase (data
not shown).
Another widely used method that enables detection of
infectious prion seeds is protein transformation. We
tested for the presence of infectious seeds by transforming
[psi-] yeast cells with purified SP14NM in 6 M GdHCl or
SP14NM sonicated fibers. Cells transformed with
SP14NM protein that was not allowed to form fibers did
not acquire the [PSI+] phenotype (Fig. 2) in over 200 col-
onies tested, while 25%–30% of cells transformed with
fibers acquired the [PSI+] phenotype (Fig. 2, data not
shown). These data suggest that preformed seeds of
SP14NM did not exist in the presence of 6 M GdHCl.
However, formally the possibility exists that seeds are
formed that are resistant to both denaturants and cause
the reaction to appear as a seeded reaction. We observed
that cells transformed with SP14NM fibers formed at 4°C
generated mostly strong [PSI+] while 25°C yielded exclu-
sively weak [PSI+] (Fig. 2). This illustrates the infectious
nature of the in vitro formed SP14NM fibers. The appear-
ance of strong and weak [PSI+] strains in cells that were
transformed with fibers formed at different temperatures
is in agreement with previously published results for
Sup35NM [42]. The concept of yeast prion strain variants
and their basis of structural variability has been studied
extensively [42-45] and is presumably recapitulated with
our repeat expansion chimeras.
In order to verify that the repeat-expanded proteins form
fibers faster than the wild type proteins, we visualized the
formation of Sup35NM and SP14NM fibers over a time
course using transmission electron microscopy (TEM). We
were able to detect very few significant structures (above
background) at five minutes with Sup35NM by TEM (Fig.
3A). Short fibers of Sup35NM became visible at 30 min-
utes and the formation of longer fibers was observed by
150 minutes (Fig. 3B, 3C). The TEM images obtained with
Sup35NM at 400 minutes (Fig. 3D) were similar to images
obtained after 24 hours of fiber formation, suggesting that
the reaction had reached completion by 400 minutes. The
TEM images supported the Th-T data which indicated that
the reaction with Sup35NM plateaued by ~200 minutes
(Fig. 1A). In contrast to wild type Sup35NM, we observed
that the repeat-expanded SP14NM formed visible short
fibers as early as five minutes and longer fibers by 30 min-
utes (Fig. 3E, 3F; compare to Fig. 4A unseeded reaction for
expanded Th-T graph of early time points). TEM images of
SP14NM suggest that fiber formation remains unchanged
between 150 minutes (Fig. 3G) and 24 hours.
Repeat-expanded prion protein cross-seeds the amyloid 
fiber formation of protein containing wild type repeat 
numbers efficiently
Prion diseases caused by oligopeptide repeat expansion
(ORE) are inherited in an autosomal dominant manner.
Patients who suffer from inherited prion disease typically
express one copy of the repeat-expanded allele and one
copy of the wild type allele [7,9]. Protein aggregates in
these patients sometimes contain both the mutant and
wild type protein [9]. One reason for the presence of both
proteins in the aggregates could be that repeat-expanded
PrP aggregates readily and cross-seeds the aggregation of
the wild type protein. Therefore, we tested whether
SP14NM seeds could enhance amyloid fiber formation of
either Sup35NM or SP5NM monomers. We observed that
SP14NM does cross-seed the aggregation of both
Sup35NM (Fig. 5A) and SP5NM (Fig. 5B) efficiently.
These data also support the previous suggestion that co-
aggregation of wild type PrP and ORE PrP is a plausible
factor in prion disease progression [9,20].
Transformation of SP14NM protein into yeast induces [PSI+]  only after fiber formation Figure 2
Transformation of SP14NM protein into yeast 
induces [PSI+] only after fiber formation. The [PSI+] 
phenotype was assayed by color on YPD, growth on SD-
ADE and curability (not shown). Control protein transforma-
tions show that protein harvested from either strong or 
weak [PSI+] cells transformed in to [psi-] cells induces the 
corresponding prion phenotype while protein harvested 
from [psi-] cells does not induce the prion state. Soluble 
SP14NM protein (SP14NMsol) does not induce the [PSI+] 
prion phenotype prior to fiber formation. SP14NM protein 
was able to induce the [PSI+] prion phenotype after fiber for-
mation either at 4°C (SP14NM4, strong strain) or 25°C 
(SP14NM25, weak strain).BMC Biochemistry 2008, 9:7 http://www.biomedcentral.com/1471-2091/9/7
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Increasing repeat length in the ORD increases both 
incorporation of monomer and lateral association of 
amyloid fibers
Since the SP14NM amyloid fiber formation occurs almost
instantaneously upon dilution from denaturant, we next
asked whether there was any effect of adding seeds. We
observed a sharp spike in fluorescence when SP14NM
seeds were added to soluble SP14NM monomers (Fig.
Unseeded SP14NM fiber formation is faster than Sup35NM fiber formation as monitored by TEM Figure 3
Unseeded SP14NM fiber formation is faster than Sup35NM fiber formation as monitored by TEM. The scale bar 
represents 100 nm. Sup35NM (5 μM) after (A) 5 min, (B) 30 min, (C) 150 min, (D) 400 min and SP14NM (5 μM) after (E) 1 
min, (F) 5 min, (G) 30 min, (H) 150 min. Representative images are shown for each time point with the exception of (H) 
because the fibers were clumped, leaving the EM grid largely empty. See Figure 7A and 7E for comparisons to 24 hour time 
point.
The addition of preformed seeds causes a spike in SP14NM fiber formation Figure 4
The addition of preformed seeds causes a spike in SP14NM fiber formation. Recombinant protein was diluted from 
denaturant (120 ×) to 2.5 μM and fiber formation was followed by Th-T fluorescence. Graphs are plotted as %RFU versus time 
and are representative of three experiments. (A) SP14NM unseeded (solid line) and SP14NM seeded (dotted line). (B) Another 
spike in Th-T fluorescence is observed after the addition of more monomer (2.5 μM) after the SP14NM fiber formation 
reached a plateau.BMC Biochemistry 2008, 9:7 http://www.biomedcentral.com/1471-2091/9/7
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4A), suggesting that fiber formation did occur by templat-
ing off of the pre-formed fiber seeds added. However, this
spike was followed by a drop in fluorescence to a steady
state level that was similar to that observed in the
unseeded reaction. This was a very intriguing observation
as no such drop in fluorescence was observed in the
seeded Sup35NM fiber formation reaction (Fig. 1A). One
possible reason for the tendency of the reaction to rapidly
reach a steady state would be the inability of the fibers to
incorporate additional soluble protein. In order to deter-
mine if the fiber ends were still competent for addition of
soluble protein, we added fresh SP14NM monomer to a
fiber formation reaction that had already reached the
steady state level of Th-T fluorescence. The addition of
SP14NM monomer at the reaction plateau caused another
spike in fluorescence (Fig. 4B), suggesting that the fibers
are still capable of adding soluble protein. Therefore, the
plateau in fluorescence observed in seeded SP14NM fiber
formation reactions was not likely due to an inability to
incorporate additional monomer.
Alternatively, the initial spike observed in the seeded
SP14NM reaction could arise due to fibers forming at the
instant the seed is added, while the ensuing drop in fluo-
rescence could result from dissociation of protein from
the fibers. The plateau would then be a result of the reac-
tion reaching an equilibrium state. To address this
hypothesis, we assessed the amount of soluble protein at
the end-point of fiber formation using a centrifugation
assay. First, all chimeras were allowed to form fibers over-
night. Then we separated the amyloid fibers from the sol-
uble protein by centrifugation and examined the protein
in the fractions by SDS-PAGE and western blot. We
observed that the amount of remaining soluble protein
decreased as the number of repeats increased (Fig. 6). The
amyloid fiber formation reaction of either SP5NM or
SP8NM showed a considerable amount of soluble protein
after an overnight incubation, as seen by the protein in the
supernatant fraction. However, there was little and no
detectable protein in the supernatant from either
SP11NM or SP14NM fiber formation reactions, respec-
tively. The lack of soluble protein remaining in the
SP14NM fiber formation reaction negated the hypothesis
Soluble protein is incorporated into fibers more efficiently in  chimeras with increased number of repeats in the ORD Figure 6
Soluble protein is incorporated into fibers more effi-
ciently in chimeras with increased number of repeats 
in the ORD. Fiber formation reactions (5 μM) were sepa-
rated into supernatant (S) and pellet (P) fractions by high 
speed centrifugation and analyzed by SDS-PAGE and western 
blot using α-Sup35 antibodies. Soluble protein remains in the 
supernatant fraction and the fibers are found in the pellet 
fraction. (T) is the total reaction prior to centrifugation.
Sup35NM and SP5NM are efficiently cross-seeded by SP14NM seeds Figure 5
Sup35NM and SP5NM are efficiently cross-seeded by SP14NM seeds. Recombinant protein was diluted from denatu-
rant (120 ×) to 2.5 μM and fiber formation was followed by Th-T fluorescence. Reactions were seeded with 2.5% (w/w) of pre-
formed sonicated fibers as indicated. Graphs are plotted as %RFU versus time and are representative of three experiments. (A) 
Fiber formation of Sup35NM. (B) Fiber formation of SP5NM.BMC Biochemistry 2008, 9:7 http://www.biomedcentral.com/1471-2091/9/7
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that the drop in fluorescence in seeded SP14NM reactions
occurred as a result of dissociation of protein from the
amyloid fibers over time.
This led us to hypothesize that the spike and drop pattern
of Th-T fluorescence seen in seeded SP14NM fiber forma-
tion reactions might be due to exclusion of Th-T binding
over time. The increase in fluorescence occurs as Th-T ini-
tially binds the rapidly forming fibers and the drop may
result from Th-T being occluded from the fibers as the
reaction progresses. In order to address this hypothesis,
we returned to TEM in order to examine the morphology
of the fibers of wild type Sup35NM and the chimeric pro-
teins. Interestingly, TEM revealed a morphological differ-
ence between the Sup35NM and SP14NM fibers. We
investigated the morphology of fibers after 24 hours of
fiber formation of all the chimeric proteins. We observed
that fibers formed from proteins with the wild type
number of repeats, Sup35NM and SP5NM did not have a
clumped morphology (Fig. 7A, 7B). However, fibers
formed from SP8NM, SP11NM, and SP14NM proteins all
exhibited a highly clumped morphology by TEM (Fig. 7C,
7D, 7E). The repeat-expanded ORD chimeric proteins
showed an increased lateral association of fully formed
fibers as compared to the fibers formed with either
Sup35NM or SP5NM. Furthermore, when fibers formed
overnight by SP14NM were sonicated, there was an
increase in Th-T fluorescence (data not shown). This sug-
gests that sonication disrupted the clumps and once again
increased the surface area for Th-T to bind the fibers. Such
an increase in fluorescence was not observed when the
same experiment was done with fibers formed from either
Sup35NM or SP5NM (data not shown). These data sup-
port the hypothesis that the difference in Th-T fluores-
cence is due to the morphological differences between the
fibers. As the fibers laterally associate and form large
clumps, sites that were previously available for Th-T bind-
ing may be unable to bind to Th-T as they interact with
other fibers. Such Th-T occlusion would cause a drop in
fluorescence.
Prion protein repeat expansion allows fiber formation in 
the presence of denaturant
In the absence of denaturant, fiber formation of
Sup35NM and SP5NM exhibits a lag phase of ~5,000 sec-
onds (Fig. 1B). However, SP8NM, SP11NM, and SP14NM
form fibers instantaneously without an appreciable lag
phase (Fig. 1B). This suggests that expansion of the repeat
region increases the propensity of the proteins to aggre-
gate. However, with these data we were unable to discern
how the propensity to aggregate increases with the change
in repeat length. There may be a gradual increase in aggre-
gation propensity with an increase in repeat number or
there may be a critical number of repeats after which the
protein forms fibers without a lag phase. To further char-
acterize the effect that increasing repeat number has on
protein aggregation, we assembled fibers in the presence
of increasing concentrations of urea. In the presence of 0.5
M urea, fiber formation of unseeded SP5NM had an
extended lag phase of approximately 10,000 seconds
(compared to 5,000 seconds in the absence of urea).
Unseeded SP8NM had a lag phase of approximately 5,000
seconds (compared to no lag phase without urea) while
the lag phases of fiber formation of either SP11NM or
SP14NM were not affected by 0.5 M urea (Fig. 8A). When
the urea concentration was increased to 1 M in fiber for-
mation reactions of SP5NM and SP8NM, the Th-T fluores-
cence did not reach a plateau within 30,000 seconds (Fig.
8B), suggesting that fiber formation did not reach comple-
tion within the same time frame as in the absence of
denaturant (Fig. 1B). SP11NM also formed fibers at a
much slower rate in the presence of 1 M urea (Fig. 8B).
However, the lag phase of SP14NM fiber formation was
not affected by 1 M urea. In the presence of 2 M urea, we
did not detect fiber formation with any of the proteins by
Th-T fluorescence (data not shown). These results suggest
The morphology of amyloid fibers formed from protein con- taining pathological versus non-pathological repeat lengths is  distinct Figure 7
The morphology of amyloid fibers formed from pro-
tein containing pathological versus non-pathological 
repeat lengths is distinct. Unseeded fiber formation reac-
tions (5 μM) were imaged by TEM after 16 hours. The length 
of scale bar represents 100 nm. (A) Sup35NM and (B) 
SP5NM have uniform dispersed fibers. (C) SP8NM, (D) 
SP11NM and (E) SP14NM have clumped fibers.BMC Biochemistry 2008, 9:7 http://www.biomedcentral.com/1471-2091/9/7
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that the propensity of the chimeric prion proteins to
aggregate is a function of the number of repeats in the pro-
tein; as the number of repeats increase, the propensity of
the proteins to aggregate gradually increases.
Prion protein repeat expansion does not enhance stability 
of amyloid fibers
ORD-expanded proteins aggregate to form amyloid fibers
much faster than the wild type protein. An interesting
question that arises from this is: Do the amyloid fibers
formed by ORD-expanded proteins differ in stability?
That is, does the expansion of the ORD enhance fiber sta-
bility? It is possible to imagine that mutations that cause
proteins to have a greater on-rate for fiber formation may
have a slower off-rate and thereby make the amyloid fiber
more stable. One way of measuring the stability of amy-
loid fibers in vitro is to examine their denaturation pro-
files. Amyloid denaturation profiles can be evaluated by
treating the fibers with increasing concentrations of
denaturant and determining the concentration at which
half of the protein is resolubilized. We measured the
denaturation profiles of the fibers formed from all of the
chimeras by determining the amount of protein remain-
ing aggregated after treatment with increasing concentra-
tions of GdHCl. Using this method, we were able to
determine the concentration of GdHCl at which the pro-
tein present in the pellet was depleted by approximately
50%. Interestingly, approximately 50% of the pelletable
protein was depleted for all the chimeras at GdHCl con-
centrations between 1.5 – 2 M (Fig. 9A), suggesting that
the ORD expansion does not enhance the stability of fib-
ers. We also measured stability of the chimeras by moni-
toring Th-T fluorescence after treatment with increasing
concentrations of GdHCl and observed that the loss of Th-
T fluorescence was similar for all chimeric proteins and
mirrored the centrifugation results (data not shown).
Next, we examined fiber stability in a temperature solubli-
zation assay. We treated fibers across a temperature gradi-
ent from 25°C to 95°C at 10°C intervals in the presence
of 2% SDS and visualized soluble protein by western blot.
We observed that 50% of the protein becomes soluble
between 55°C – 65°C for all the chimera fibers (Fig. 9B).
Taken together, these data suggest that the stability of the
amyloid fibers formed by the chimeric proteins is the
same, irrespective of the ORD repeat length.
Discussion
In this study, we characterized the biochemical properties
of a set of chimeric prion proteins wherein the ORD of
Sup35p was replaced with that of PrP. The chimeric prion
proteins were created by substituting the endogenous
Sup35p ORD with the repeat domain of PrP containing
five, eight, 11 and 14 oligopeptide repeats [40]. The
repeat-expanded proteins show a remarkable set of prop-
erties that highlight their enhanced ability to aggregate
and form amyloid fibers in vitro. These data agree with
work done by others in which recombinant PrP (rPrP)
with ORD expansions exhibit an enhanced ability to form
amyloid fibers with increasing number of repeats [20,46].
Our data also support previous work done with transgenic
Expansion of the ORD enhances fiber formation in the presence of the denaturant urea Figure 8
Expansion of the ORD enhances fiber formation in the presence of the denaturant urea. Recombinant protein was 
diluted from denaturant (120 ×) to 2.5 μM and fiber formation was followed by Th-T fluorescence. Fiber formation of chimeric 
proteins SP5NM, SP8NM, SP11NM and SP14NM in (A) 0.5 M Urea FFB (B) 1 M Urea FFB is shown. Data in the graphs are rep-
resentative of two experiments.BMC Biochemistry 2008, 9:7 http://www.biomedcentral.com/1471-2091/9/7
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mice (Tg(PG14)) that express PrP harboring nine addi-
tional octapeptide repeats. These mice manifest a sponta-
neous form of prion disease [21]. Although the
spontaneous form of the disease in the Tg(PG14) mice is
not infectious, the protein aggregates and the animals dis-
play many of the histopathological hallmarks that are
characteristic of prion diseases in mammals [23].
In humans, there is a high degree of heterogeneity with
respect to the age of onset and disease progression in peo-
ple that have mutations in the PRNP  gene [19,47,48].
There is a weak inverse correlation between the number of
repeats and the age of onset of disease [19]. Further,
repeat-expanded proteins have also been proposed to
interact with the wild type PrP protein. Examination of
amyloid plaques from patients with one copy of wild type
PrP and one copy of mutant PrP demonstrated the pres-
ence of both the wild type and the mutant forms of the
protein in the same plaques [9]. It has also been shown
that mixing repeat-expanded rPrP with wild type rPrP
enhances fiber formation of wild type rPrP [20]. These
data suggested that there may be co-aggregation or cross-
seeding between the mutant and wild type proteins. Our
data also supports the cross-seeding model of disease pro-
gression since SP14NM shows efficient cross-seeding of
both Sup35NM and SP5NM.
We observed that an increase in the number of repeats
enhanced the ability of the protein to form fibers to the
extent that the lag phase observed during most amyloid
fiber formation reactions was lost. In addition, the pro-
teins harboring repeat expansions had an enhanced abil-
ity to form fibers in the presence of denaturant.
Interestingly, comparing our data to a recent study [25]
suggests that the presence of heterogeneous repeats, that
is, a combination of one Sup35p repeat with eight repeats
from the PrP protein, forms amyloid fibers slower than
having eight repeats from PrP only (Fig. 1B). This suggests
that the enhanced amyloid formation with repeat expan-
sion is affected by repeat homogeneity. Strikingly, our
data suggests seeding of fibers with proteins having differ-
ent (Sup35p or PrP) repeats appears to be as efficient as
seeding with proteins that harbor same repeats (Fig. 5B).
Previous work by Serio et al. suggested a nucleated confor-
mational conversion model of amyloid fiber formation of
The stability of the prion protein fibers is not enhanced by expansion of the repeat domain Figure 9
The stability of the prion protein fibers is not enhanced by expansion of the repeat domain. (A) Fibers were 
formed overnight, treated with GdHCl (0 M, 0.5 M, 1.0 M, 1.5 M and 2 M) denaturant and then separated into soluble and pel-
let fractions by centrifugation (16,000 × g). Samples were analyzed by SDS-PAGE and western blotted using α-Sup35 antibod-
ies. Bands were quantified using ImageJ software. (B) Fibers of SP5NM ( ), SP8NM ( ), SP11NM ( ) and SP14NM () were 
formed overnight, treated across a temperature gradient in the presence of 2% SDS. Following SDS-PAGE and western blot, 
gel bands were quantified using ImageJ software and and best fit lines were graphed using SigmaPlot software.BMC Biochemistry 2008, 9:7 http://www.biomedcentral.com/1471-2091/9/7
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Sup35NM [49]. An important aspect of this model is that
the rate limiting step for fiber formation, manifested as
the lag phase, is the conformational conversion of the
nucleus to establish a competent seed. One implication of
this model is that rate of fiber formation is not linearly
dependent on initial concentration of protein. Serio et al.
showed that the lag phase of Sup35NM fiber formation
was not affected significantly by the initial protein con-
centration. We observed that the lag phase of SP14NM
fiber formation, albeit an extremely short lag phase, is also
not affected by initial protein concentration. In fact, even
when the concentration of SP14NM protein was only 0.25
μM in unseeded fiber formation reactions, the lag phase
of fiber formation was identical to that of 5 μM protein
(data not shown). Our kinetic data suggest that the
SP14NM nucleus has an enhanced ability to undergo con-
formational conversion to the extent that the lag phase of
fiber formation is virtually eliminated. As previously sug-
gested [43], one mechanism that could explain the
decrease in lag phase for fiber formation is that the
expanded ORDs have transient β-sheet structures that are
formed due to intramolecular contacts, which may reduce
the number of intermolecular contacts required to obtain
a stabilized structure to nucleate fiber formation. This
would suggest that if a monomer can undergo the appro-
priate conformational changes and maintain that confor-
mation through intramolecular contacts, then the protein
may not need to form oligomers in order to form fibers.
Currently, it is unclear if the growth of amyloid fibers in
general occurs through linear addition of monomers or
intermediate fibers [50,51]. Different amyloidogenic pro-
teins may have distinct mechanisms for the growth of
amyloid fibers [52]. Work done by others suggests that
fibers formed by Sup35NM occurs by monomer addition
[51], however, in the case of the A-beta peptide, an oligo-
meric intermediate may be necessary for fiber growth
[53,54]. One current model for the growth of poly-Q pep-
tides suggests that a single molecule, after undergoing
conformational conversion, may act as a nucleus capable
of templating the addition of monomers, thereby result-
ing in the growth of amyloid fibers [50]. Therefore, it is
plausible that for PrP molecules with expanded ORDs, the
mechanism of amyloid fiber assembly and growth
changes such that the formation of an oligomer for initia-
tion or growth of fibers is no longer required.
In addition to the ability of repeat-expanded proteins to
form a competent seed more readily, a difference in the
pathological and non-pathological repeat expansions
may be in the efficiency with which monomer is added to
the fibers. Our data from the centrifugation assay suggests
that the ability of the conformationally-converted nucleus
to incorporate soluble protein increases as the number of
repeats increase. Currently, a debatable idea in the amy-
loid field is the existence of a critical concentration in
amyloid fiber formation reactions. It has been suggested
that the addition of monomer to the fibers may be revers-
ible [55]. Therefore, by assaying the amount of monomer
remaining at the end point, we could potentially deter-
mine the relative critical concentrations [56]. As such, our
data from the centrifugation assay may also suggest that as
the number of repeats in the ORD increases, the critical
concentration decreases. However, we do not know if
these reactions are in fact reversible.
Since the repeat-expanded proteins form fibers faster and
incorporate monomer more efficiently, we hypothesized
that the fibers formed may also be more stable. However,
the increased repeat length did not alter amyloid stability
as assessed by denaturation in GdHCl or resolubilization
by heat treatment. We observed no significant shift in the
concentration of GdHCl or the range of temperature that
resolublized ~50% of the fibers formed by the chimeras.
This suggests that, irrespective of which mutant repeat
expansion protein is found from patient to patient, the
clearance of the aggregates might be equally challenging
to the cellular machinery. One reason for the lack of dif-
ference in stability might be that the amyloid core of the
fibers does not change significantly between fibers formed
with the various repeat-expanded monomers. We crudely
assessed changes in the amyloid core of the fibers by treat-
ing the fibers with various proteases and determining the
pattern of protease resistant fragments. We observed sim-
ilar patterns of protease resistant fragments for all of the
ORD-expanded proteins (chymotrypsin, V8, proteinase K;
data not shown). This suggests that the amyloid core of all
the fibers, regardless of the monomer used to form the fib-
ers, might be the same. In order to conclusively determine
the amyloid core of all these proteins, however, more sen-
sitive biophysical assays are required.
From our previous in vivo experiments [40], we noted that
SP14NM can maintain the [SP14+] prion phenotype in
weak and strong variants similar to the wild type [PSI+].
However, a very unique characteristic of the [SP14+] prion
lies in its ability to interconvert between weak and strong
variants at a high frequency. One explanation for the abil-
ity of [SP14+] to interconvert variants readily may be that
the amyloid core does not change significantly between
the two variants. Therefore, the protein would readily be
able to adopt either conformation and thereby switch var-
iants at a high frequency. This differs from wild type
Sup35p, where weak and strong strains of the [PSI+] prion
have different amyloid cores [43,45]. The recent study by
Toyama  et al. shows that the first 40 amino acids of
Sup35p are part of the amyloid core for [PSI+] strains [45].
Interestingly, data published by our lab demonstrates that
the repeat expansion can overcome the requirement of the
first 40 amino acids in prion propagation [40]. Taken
together, and discounting the obvious technical differ-BMC Biochemistry 2008, 9:7 http://www.biomedcentral.com/1471-2091/9/7
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ences between all of these studies, the data suggest that
there may be multiple ways to generate prions and struc-
tural variants [40,43,45]. The strain variants observed in
yeast can be used as a model to study the phenotypic het-
erogeneity that is exhibited by strains of prion disease. The
ability of [SP14+] prion to interconvert between variants
rapidly may provide an avenue to investigate the mecha-
nisms underlying the high degree of phenotypic heteroge-
neity observed with prion diseases that arise due to repeat
expansions in PRNP.
Conclusion
In summary, biochemical characterization of the repeat
expanded proteins demonstrated that the proteins har-
boring repeat expansions of pathological length have a
greater propensity to aggregate and have a considerably
shorter lag phase in fiber formation. The morphology of
the fibers is also different between the non-pathological
and pathological repeat expansions. Amyloid fibers
formed with repeat-expanded proteins clump into large
aggregates, whereas the fibers formed by proteins that do
not have repeat expansions do not laterally associate to
the same extent. Chimeras with the disease-associated
repeat expansions proved to be more efficient at convert-
ing soluble protein into the aggregated state than the pro-
teins containing wild type repeat numbers. In addition,
the fibers formed from all proteins showed similar dena-
turation and solubilization profiles when treated with
guanidine hydrochloride (GdHCl) or heat. Together, our
data suggest that the expansion of the ORD in PrP results
in an increased propensity of the protein to convert from
the native conformation to an aggregated conformation,
but does not alter the stability of the amyloid fibers
formed.
Methods
Protein expression and purification of recombinant 
proteins
Sup35NM was purified as reported previously [57].
SP5NM, SP8NM, SP11NM and SP14NM were subcloned
(from [40]) into the vector pET22. Protein was expressed
in BL21(DE3)pLysS Escherichia coli cells grown in Cir-
cleGrow® medium containing chloramphenicol (34 μg/
ml) and ampicillin (100 μg/ml). Protein expression was
induced with 1 mM IPTG, at OD600~0.6 at 24°C for four
and a half hours. The bacterial pellet was resuspended in
buffer A (8 M urea, 10 mM Tris-HCl, pH 7.5) and gently
agitated at room temperature for 20 minutes. The cell
debris was removed by centrifugation for 30 minutes at
17,000 rpm in a Sorvall SS-34 rotor. The supernatant was
loaded onto a Q-Sepharose (GE HealthCare) column and
the protein was eluted with a linear gradient of sodium
chloride (0 – 1 M NaCl). Fractions containing the protein
were loaded onto a hydroxyapatite column (BIO RAD)
equilibrated with buffer C (8 M Urea, 5 mM KPO4, pH
6.8). The protein was eluted with a linear gradient of
potassium phosphate (5–500 mM). Fractions containing
the protein were determined by SDS-PAGE and coomassie
staining. The fractions containing the protein were pooled
and dialyzed against Buffer A and stored in methanol at -
80°C.
Amyloid Fiber Formation Kinetics
Recombinant protein was methanol-precipitated and
resuspended in 6 M GdHCl. Protein concentration was
determined by measuring the OD at 280 nm. The protein
was diluted 120-fold in FFB buffer (150 mM NaCl, 5 mM
KPO4, pH 7.5) for fiber formation assays. Fiber formation
was followed by monitoring Thioflavin-T binding (100-
fold excess). Thioflavin-T fluorescence was continuously
measured using PTI Quantamaster spectrofluorometer
(Photon Technology International, Inc., Santa Clara, CA).
Electron Microscopy
Samples of fibrillar Sup35NM, SP5NM, SP8NM, SP11NM
and SP14NM were allowed to settle onto freshly glow-dis-
charged 200 mesh carbon-formvar coated copper grids for
5 minutes. Grids were then rinsed twice with water and
stained with 1% uranyl acetate (Ted Pella) for one minute.
Samples were viewed on a JEOL 1200EX transmission
electron microscope (JEOL USA).
Centrifugation Assay
Amyloid fibers were formed by incubating recombinant
protein diluted 120-fold in FFB overnight at room temper-
ature while rotating end-over-end. The reaction was sepa-
rated into pellet and supernatant fractions by
centrifugation (16,000 × g, 20 minutes). The total, super-
natant and pellet fractions were separated by SDS-PAGE
and analyzed by western blot using α-Sup35 antibodies.
GuanidineHydrochloride (GdHCl) denaturation profile
Recombinant protein was diluted 120-fold in FFB and
incubated at room temperature on a rotator overnight.
The fibers were treated with increasing concentrations
(0–2 M) of GdHCl for 30 minutes. The treated fibers were
then separated into supernatant and pellet fractions by
centrifugation (16,000 × g, 20 minutes). The pellet frac-
tions were separated by SDS-PAGE and analyzed by west-
ern blot using α-Sup35 antibodies. The band intensities
were quantified using ImageJ software.
Temperature resolubilization assay
Recombinant protein was diluted 120-fold in FFB and
incubated at room temperature on a rotator overnight.
These fibers were then incubated across a temperature gra-
dient (25°C – 95°C, 10°C intervals) for 5 minutes in the
presence of 2% SDS. After the heat treatment, the samples
were analyzed by SDS-PAGE and western blot. TheBMC Biochemistry 2008, 9:7 http://www.biomedcentral.com/1471-2091/9/7
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amount of protein that entered the gel was determined by
quantifying the bands using ImageJ software.
Protein transformation
Protein transformation into 74-D694 yeast strain was
conducted as described in Ref. [58].
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